• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SD filed by Henry Schein Inc.

    5/30/25 4:18:14 PM ET
    $HSIC
    Medical Specialities
    Health Care
    Get the next $HSIC alert in real time by email
    SD 1 formsdconflictmineral.htm FORM SD 2024 formsdconflictmineral
     
     
     
     
     
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM SD
    Specialized Disclosure Report
    HENRY SCHEIN, INC.
    (Exact name of registrant as specified in its charter)
    DELAWARE
    0-27078
    11-3136595
    (State or other jurisdiction
    (Commission File
    (IRS Employer
    of incorporation)
    Number)
    Identification No.)
    135 DURYEA ROAD, MELVILLE,
     
    NEW YORK
    11747
    (Address of principal executive offices)
    (Zip Code)
    Kelly Murphy, Senior Vice
     
    President and General Counsel
    (631) 843-5500
    (Name and telephone number, including area code, of the person to contact in connection with this report.)
    Check the appropriate box to indicate the rule pursuant to which this form is being filed, and
    provide the period to which the information in this form applies:
     
    [X] Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period
    from January 1, 2024 to December 31, 2024.
     
    Section 1 – Conflict Minerals Disclosure
    Item 1.01.
     
    Conflict Minerals Disclosure and Report
    Conflict Minerals Disclosure
    This disclosure for the calendar year ended December 31, 2024 is presented to comply with Rule
    13p-1 under the Securities Exchange Act of 1934 (the “Rule”).
     
    The Rule imposes certain
    reporting obligations on Securities and Exchange Commission registrants whose manufactured
    products contain conflict minerals which are necessary to the functionality or production of their
    products. Conflict Minerals are defined as cassiterite, columbite-tantalite, gold, wolframite, and
    their derivatives, which are limited to tin, tantalum, and tungsten.
     
    These requirements apply to
    registrants whatever the geographic origin of the Conflict Minerals and whether or not they fund
    armed conflict.
    If a registrant conducts a Reasonable Country of Origin Inquiry (“RCOI”) and determines that
    the conflict minerals originated from sources other than the Democratic Republic of the Congo
    or an adjoining country (the “Covered Countries”), or from recycled and scrap sources, they are
    required only to submit a Form SD, which describes the RCOI.
    Although a substantial percentage of the products we sell are purchased from third-party
    suppliers as finished products, we manufacture or contract with third parties to manufacture a
    portion of our product portfolio.
     
    We determined that certain of those products contain Conflict
    Minerals that are necessary to their functionality or production.
     
    To determine if the Conflict Minerals in our manufactured and other covered products originated
    from sources in the Covered Countries, we conducted a RCOI in good faith.
     
    We surveyed all
    known suppliers from whom we purchase materials containing the Conflict Minerals and
    reviewed the available public websites of such known suppliers.
     
    We also utilized the
     
    Responsible Minerals Initiative’s Conflict Minerals Reporting Template
     
    (CMRT) to obtain the
    relevant data.
     
    The responses to our inquiry and results of our review can be grouped into the two categories
    identified below:
    ●
    The supplier represented that its products do not contain Conflict Minerals from the
    Covered Countries.
    ●
    The supplier represented that its products contain Conflict Minerals from the Covered
    Countries but they have implemented reasonable due diligence measures and
    practices to ensure responsible sourcing (
    e.g.
    , participate in Conflict-Free Smelter
    Program assessment protocols).
    As a result of our RCOI, we have no reason to believe that our necessary Conflict Minerals (i)
    may have originated in the Covered Countries or (ii) if they originated in the Covered Countries,
    failed to meet conflict-free sourcing or the Conflict-Free Smelter Program assessment protocols.
    This Form SD is publicly available at investor.henryschein.com.
     
    The website and information
    accessible through it are not incorporated into this document.
    Item 1.02.
     
    Exhibit
    Not applicable.
    Section 2 – Exhibits
    Item 2.01.
     
    Exhibits
    Not applicable.
     
     
    SIGNATURE
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
    caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
    HENRY SCHEIN, INC.
    By: /s/ KELLY
     
    MURPHY
    Kelly Murphy
    Senior Vice President and General Counsel
    Dated: May 30, 2025
    Get the next $HSIC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HSIC

    DatePrice TargetRatingAnalyst
    7/25/2025$75.00Buy → Hold
    Stifel
    7/14/2025$72.00Outperform → Neutral
    Robert W. Baird
    2/14/2025$80.00Equal Weight
    Wells Fargo
    1/6/2025$69.00 → $84.00Underperform → Buy
    BofA Securities
    12/4/2024$75.00Neutral
    Mizuho
    7/22/2024$81.00 → $92.00Neutral → Outperform
    Robert W. Baird
    2/26/2024$78.00Market Perform
    Leerink Partners
    12/12/2023$71.00 → $82.00Neutral → Overweight
    JP Morgan
    More analyst ratings

    $HSIC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Henry Schein downgraded by Stifel with a new price target

    Stifel downgraded Henry Schein from Buy to Hold and set a new price target of $75.00

    7/25/25 8:58:32 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein downgraded by Robert W. Baird with a new price target

    Robert W. Baird downgraded Henry Schein from Outperform to Neutral and set a new price target of $72.00

    7/14/25 8:40:13 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Wells Fargo initiated coverage on Henry Schein with a new price target

    Wells Fargo initiated coverage of Henry Schein with a rating of Equal Weight and set a new price target of $80.00

    2/14/25 7:05:26 AM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Henry Schein's 28th Annual 'Back to School' Program Supports Students Worldwide

    With Backpacks Full of Supplies, Team Schein Helps Equip Children to Thrive in the Classroom For the 28th consecutive year, Henry Schein, Inc. (NASDAQ:HSIC) is helping students worldwide start the academic year off right through its "Back to School" program, a flagship initiative of Henry Schein Cares, the Company's global corporate citizenship program. Team Schein Members (TSMs) at 45 locations in the U.S., Canada, Italy, Spain, the U.K., and Ireland are helping more than 5,200 students gain confidence and excitement for the school year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250818808698/en/On August 14, Henry Schein

    8/19/25 6:30:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein Reports Second Quarter 2025 Financial Results

    Second-quarter 2025 GAAP diluted EPS of $0.70, compared to $0.80 GAAP diluted EPS in the second quarter of 2024 Second-quarter 2025 non-GAAP diluted EPS of $1.10, compared to $1.23 non-GAAP diluted EPS in the second quarter of 2024 Maintains guidance for 2025 non-GAAP diluted EPS of $4.80 to $4.94, mid-single digit 2025 Adjusted EBITDA growth, and sales growth of 2% to 4% Takes next steps in collaboration with KKR to pursue additional opportunities to create shareholder value Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today reported financial results for the second quarter ended June

    8/5/25 6:00:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein One Launches Forms to Make Patient Check-In Easier and Faster

    With a native end-to-end workflow in Dentrix and Dentrix Ascend, the new Forms cuts manual work and extra logins for a smoother start to every visit Henry Schein One, the most connected solution in dental technology, today launched Forms for Dentrix and Dentrix Ascend (Ascend). With more than 1,000 dental practices adopting Forms just this month, this fully integrated digital intake solution is already simplifying the pre-appointment process for both patients and dental teams. With mobile-friendly and customizable forms, ID and insurance card scanning, and secure two-factor authentication, Forms makes patient check-in virtually touchless. And early results show that 90% of patients comple

    7/30/25 6:30:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    SEC Filings

    View All

    SEC Form 10-Q filed by Henry Schein Inc.

    10-Q - HENRY SCHEIN INC (0001000228) (Filer)

    8/5/25 3:03:18 PM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - HENRY SCHEIN INC (0001000228) (Filer)

    8/5/25 6:15:01 AM ET
    $HSIC
    Medical Specialities
    Health Care

    SEC Form 8-K filed by Henry Schein Inc.

    8-K - HENRY SCHEIN INC (0001000228) (Filer)

    7/15/25 7:10:41 AM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Kkr Hawaii Holdings L.P. claimed ownership of 15,263,662 shares (SEC Form 3)

    3 - HENRY SCHEIN INC (0001000228) (Issuer)

    8/15/25 9:30:38 PM ET
    $HSIC
    Medical Specialities
    Health Care

    SEC Form 4 filed by Large owner Kkr Hawaii Aggregator L.P.

    4 - HENRY SCHEIN INC (0001000228) (Issuer)

    8/14/25 7:00:45 PM ET
    $HSIC
    Medical Specialities
    Health Care

    Chairman, CEO Bergman Stanley M gifted 1,650 units of Common Stock par value $0.01 per shre, decreasing direct ownership by 0.51% to 322,097 units (SEC Form 4)

    4 - HENRY SCHEIN INC (0001000228) (Issuer)

    8/14/25 4:50:03 PM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Daniel William K bought $670,800 worth of shares (10,000 units at $67.08) (SEC Form 4)

    4 - HENRY SCHEIN INC (0001000228) (Issuer)

    8/11/25 4:26:33 PM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    Financials

    Live finance-specific insights

    View All

    Henry Schein Reports Second Quarter 2025 Financial Results

    Second-quarter 2025 GAAP diluted EPS of $0.70, compared to $0.80 GAAP diluted EPS in the second quarter of 2024 Second-quarter 2025 non-GAAP diluted EPS of $1.10, compared to $1.23 non-GAAP diluted EPS in the second quarter of 2024 Maintains guidance for 2025 non-GAAP diluted EPS of $4.80 to $4.94, mid-single digit 2025 Adjusted EBITDA growth, and sales growth of 2% to 4% Takes next steps in collaboration with KKR to pursue additional opportunities to create shareholder value Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today reported financial results for the second quarter ended June

    8/5/25 6:00:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein to Webcast Second Quarter 2025 Conference Call on Tuesday, August 5, 2025, at 8:00 a.m. ET

    Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, announced today that it will release its second quarter 2025 financial results before the stock market opens on Tuesday, August 5, 2025, and will provide a live webcast of its earnings conference call on the same day beginning at 8:00 a.m. Eastern time. Speakers on the call will include Stanley M. Bergman, Chairman of the Board and Chief Executive Officer of Henry Schein, and Ronald N. South, Senior Vice President and Chief Financial Officer. Investors can access the call by visiting https://investor.henryschein.com/webcasts. A replay will be available

    7/22/25 6:30:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein Reports First Quarter 2025 Financial Results

    First-quarter 2025 GAAP diluted EPS of $0.88, growth of 22% compared to the first quarter of 2024 First-quarter 2025 non-GAAP diluted EPS of $1.15, growth of 4.5% compared to the first quarter of 2024 Maintains guidance for 2025 non-GAAP diluted EPS of $4.80 to $4.94, mid-single digit 2025 Adjusted EBITDA growth, and sales growth of 2% to 4% Repurchased $161 million of common stock, or approximately 2.3 million shares Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today reported financial results for the first quarter ended March 29, 2025. "We are pleased with our first quarter financial re

    5/5/25 6:00:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    Leadership Updates

    Live Leadership Updates

    View All

    Stanley M. Bergman to Retire as Henry Schein's Chief Executive Officer at the End of 2025

    Mr. Bergman to Continue to Serve as Chairman of the Board Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, announced today that Stanley M. Bergman will retire as Chief Executive Officer (CEO) at the end of the year after 45 years at the Company, including more than 35 years as CEO. Mr. Bergman will continue to lead Henry Schein in his current role until his retirement and will remain as Chairman thereafter. The Board is commencing a formal search process in conjunction with a nationally recognized executive search firm and will consider internal and external candidates. "With the progress made advan

    7/15/25 7:05:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein Announces Completion of Strategic Investment by KKR and Appointment of Dan Daniel to Board of Directors

    Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today announced the successful completion of a $250 million strategic investment by funds affiliated with KKR, a leading global investment firm. Upon the closing of this transaction, KKR has become the holder of approximately 12% of the common shares of Henry Schein. In connection with the investment, William K. "Dan" Daniel, Executive Advisor to KKR and former Executive Vice President of Danaher Corporation, has officially joined Henry Schein's Board of Directors as an independent director. He joins Max Lin, Partner at KKR and leader of the firm's Healt

    5/16/25 4:10:00 PM ET
    $HSIC
    $KKR
    Medical Specialities
    Health Care
    Investment Managers
    Finance

    PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

    Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthca

    3/11/25 7:05:00 AM ET
    $BAX
    $BMRN
    $EMBC
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Medical Specialities

    $HSIC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Henry Schein Inc.

    SC 13G/A - HENRY SCHEIN INC (0001000228) (Subject)

    11/13/24 3:30:01 PM ET
    $HSIC
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Henry Schein Inc.

    SC 13G - HENRY SCHEIN INC (0001000228) (Subject)

    11/12/24 9:32:27 AM ET
    $HSIC
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Henry Schein Inc. (Amendment)

    SC 13G/A - HENRY SCHEIN INC (0001000228) (Subject)

    2/14/24 11:18:57 AM ET
    $HSIC
    Medical Specialities
    Health Care